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Abstract
MRL/Mp-lpr/lpr autoimmune mice consistently show an
- 25% incidence of the systemic lupus eyrthematosus marker
autoantibody anti-Sm. In the present report, we show that the
failure to find anti-Sm antibodies in three-quarters of 5-mo-old
MRL/lpr mice was not an artifact of an insensitive assay, but
rather that the mice fell into two populations as regards their
anti-Sm positivity. Based on an extensive analysis of the inci-
dence of anti-Sm positivity in 5-mo-old mice according to their
cage of residence, we found no evidence for genetic, environ-
mental, or parental influences on the propensity of an individ-
ual animal to become anti-Sm positive. Also, the gender of the
mouse, its Sm antigen level, or its length of survival were not
related to anti-Sm antibody, nor was the anti-Sm antibody
status of either parent. Some animals became anti-Sm positive
after 5 mo of age, but this was less likely than becoming posi-
tive before 5 mo of age. Finally, a survey of 205 autoimmune
C57BL/6-lpr/lpr mice confirmed the uniqueness of the MRL
background for this autoantibody response. These results to-
gether indicate that the possibility of making anti-Sm antibod-
ies is under genetic control, but that the expression of this
capability in an individual animal is governed by stochastic
events. We hypothesize further that such random processes
may involve the expression of particular immunoglobulin vari-
able-region genes combined with mechanisms of extensive so-
matic mutation or positive feedback amplification, which
would transmute an initial monoclonal response into an even-
tual polyclonal one.
Introduction
MRL/Mp-/pr//pr (MRL/Ipr)' mice are highly inbred and re-
producibly develop an autoimmune syndrome resembling
human systemic lupus erythematosus (SLE) (1). This strain
and its congenic partner MRL/Mp-+/+ (MRL/+), which de-
velops a more indolent autoimmune disease, are particularly
interesting because they produce high titers of autoantibodies
to the nuclear ribonucleoprotein Sm (2). The spontaneous pro-
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duction of anti-Sm antibodies is a highly specific marker for
the diagnosis of SLE in mice, humans, and dogs (3, 4, 5).
We have been studying the immunoregulation of the anti-
Sm response in MRL/lpr mice as a model of a significant SLE
autoantibody. In our initial studies, we reported that - 25% of
the MRL/lpr animals became anti-Sm positive (3). This pro-
portion was similar to that found in outbred populations of
humans and dogs with SLE (4, 5). In humans, some studies
have suggested that genetics might determine whether an indi-
vidual potentially becomes anti-Sm positive (6). However, the
MRL mice have been inbred since the early 1970s, and, thus,
the individuals of the strain should be near complete genetic
homogeneity, unless there is selective reason for enforced het-
erozygosity. It is, thus, of considerable interest to determine
why only a minority of MRL//pr mice develop anti-Sm anti-
bodies.
In this study, we have investigated several potential param-
eters that could control whether or not an individual MRL/lpr
mouse becomes anti-Sm positive. We have also compared the
MRL/lpr mice with the C57BL/6-lpr/lpr(B6-/pr) mice to dis-
tinguish between the contributions of the lpr gene and those of
the MRL background. Our results indicate that although the
predisposition to make anti-Sm antibodies in autoimmune lpr
homozygous mice is under genetic control, the expression of
this potential in an individual MRL/lpr animal is governed by
stochastic events with a defined probability.
Methods
Mice. The MRL/lpr, MRL/+, and B6-lpr mice were originally ob-
tained from the Jackson Laboratory, Bar Harbor, ME, and have been
bred in our colony at the University ofNorth Carolina. The epidemiol-
ogy experiments were performed on cohorts ofmice from 1979 to 1980
and from 1982 to 1983. The mice were weaned at age 3-4 wk and then
caged such that siblings of the same sex were housed together. Mice
were bled at the indicated ages by retroorbital puncture, and sera were
stored for short periods at 40C or for longer periods at -20°C. Normal
mice were C57BL/6 and bml2 from our colony.
Anti-Sm assays. The detection of anti-Sm antibodies by double
immunodiffusion was performed, as previously described, using a
human SLE anti-Sm reference serum (7). The anti-Sm enzyme-linked
immunoabsorbent assay (ELISA) utilized an affinity-purified prepara-
tion of Sm from rabbit thymus extract (8, 9). Sera were tested in
dilutions of l0-3_lo-6, and antibodies were detected by a biotinylated
affinity-purified goat anti-mouse IgG (pFc' specific) followed by avi-
din-alkaline phosphatase and paranitrophenyl phosphate. In assays
comparing positive and negative mice, each sample was tested in the
presence and absence of 100 Ag/ml of the Fab fragments of human
anti-Sm Igp to ensure specificity in each case. Data analysis in these
assays utilized the difference between the optical densities (ODs) ob-
tained with and without the Fab fragments. To quantitate the level of
anti-Sm antibodies in individual sera in some experiments, each
serum was tested at dilutions, and a titer was determined as the point
where a graph of the dilution vs. OD for that serum crossed a standard
OD of 0. 100.
Sm antigen was detected by ELISA utilizing F(ab')2 fragments ofan
affinity-purified anti-Sm antibody from a human source. Mouse tis-
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sues were harvested from freshly killed animals and homogenized in
borate-buffered saline with 0.1% NP-40 as described (10).
Statistical analysis. Data analysis was performed by Dr. Sandra
Stinnett at the Biometric Consulting Laboratory, Department of Bio-
statistics, University of North Carolina. For the cage analysis, the ex-
pected distribution of trait (i.e., anti-Sm)-positive animals in cages
containing varying numbers ofmice was calculated using the binomial
distribution formula E(x) = (;) PI(I - P)" - x, where n is the number of
cages ofeach cage size; x, the number ofmice with the trait; and P, the
overall probability of developing the trait in the population. In the
pooled population from two experiments, 75 out of 336 mice were
anti-Sm positive at age 5 mo for an overall probability of0.223. Simi-
larly, the distribution of the trait by litter size was determined in the
second experiment, with 142 mice, in which the litter size was defi-
nitely known. All comparisons were tested for goodness of fit by chi-
square analysis.
Results
Genetics of anti-Sm. We have previously reported that anti-
Sm antibodies are rarely found in any unmanipulated mice
other than those of the MRL strains, both MRL/lpr and
MRL/+ (3). These observations indicated that the MRL back-
ground was sufficient for anti-Sm production. Since the lpr
gene on other backgrounds causes the production of various
autoantibodies, it was possible that it could also induce anti-
Sm. We have therefore utilized the anti-Sm ELISA assay to
compare levels of anti-Sm antibodies in B6-lpr mice with
those in MRL/lpr mice. 205 B6-lpr sera from male and female
mice aged 2-14 mo were tested at a 1:1,000 dilution. One
mouse showed an OD of0.302. No other mouse had an OD of
> 0.200, and only 11 additional sera had ODs > 0.100 (Table
I). In contrast, all eight anti-Sm positive MRL/lpr sera gave
corrected ODs of > 0.270, even when tested at a 1:10,000
dilution. These results indicate that the B6 strain lacks the
genetic ability to make anti-Sm antibodies spontaneously,
even in the presence of a homozygous lpr gene. In an addi-
tional set of experiments, we tested MRL/+ mice from the
colony at the University of North Carolina. From a group of
50 animals aged 11-21 mo, 15 (30%) were typed as anti-Sm
positive by double immunodiffusion. No obvious age effect
was seen, as 5 out of 18 (28%) animals aged 11-13 mo and 10
out of 32 (31%) animals aged 16-21 mo were positive. There-
fore, in contrast to our earlier findings on a small number of
mice (3), the prevalence of positivity in the MRL/+ mice was
similar to that seen in MRL/lpr mice.
Analysis of anti-Sm positivity by ELISA. It was possible
that the failure to detect anti-Sm antibodies in a majority of




















Figure 1. Bimodal dis-
tribution of anti-Sm an-
tibodies in 5-mo-old
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hibitor. Resultant ODs
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dilution giving a stan-
dard OD of 0.100 was
interpolated as the
ELISA titer.
ity of the double immunodiffusion assay or to the delayed
development of positivity in certain animals. To analyze the
first issue, we performed quantitative ELISA assays on serial
dilutions of sera from 5-mo-old MRL/lpr mice identified as
positive by double immunodiffusion. We compared these
ELISA titers with those of age- and sex-matched immunodif-
fusion negative mice. Fig. 1 shows results with male mice. The
ELISA titers of the immunodiffusion positive and negative
sera clearly fell into two distinct populations, which differed by
two to three orders of magnitude. Fig. 2 shows a similar com-
parison between 5-mo-old MRL/lpr male mice that were nega-
tive for anti-Sm by immunodiffusion and normal mice that
had no known autoimmunity. The MRL/lpr mice showed no
indication of a response to the Sm antigen beyond that of the
"normal background." (Whether this normal background is
specific or nonspecific we do not know, although the fact that
it is poorly inhibitable by anti-Sm Fab fragments suggested the
latter.) Therefore, the division of MRL/lpr mice into anti-Sm
positive and anti-Sm negative groups is not an artifact of an
insensitive assay; rather, the mice are distributed in a bimodal
population with regard to this trait. Similar results were ob-
tained with female mice and in a separate repeat experiment
(data not shown).
The second issue is whether the 0.25 incidence of anti-Sm
positivity is related to the age at which we sampled the mice.
To analyze this question, we determined the incidence density
of the development of anti-Sm positivity in a group of mice
bled biweekly from the age of 3 mo. Levels of anti-Sm anti-
Table I. Anti-Sm Antibodies by ELISA in lpr Mice
Corrected OD 405
Strain n Immunodiffusion Dilution >0.300 0.200-0.299 0.100-0.199 0-0.099
C57BL/6-lpr 205 ND 10-3 1 0 11 193
MRL/lpr 8 + 10-4 6 2 0 0
10-5 4 1 2 1
MRL/lpr 2 - 1O-4 0 0 0 2
* Anti-Sm antibodies by immunodiffusion.
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bodies of the IgM, IgGl, IgG2a, IgG2b, and IgG3 isotypes
were determined in all sera. The details of this isotype analysis
will be presented elsewhere (1 1). For the current analysis we
looked at the onset ofanti-Sm positivity as the attainment ofa
certain OD value for any isotype in the anti-Sm ELISA. As
this is an arbitrary criterion, several values were studied. We
then determined the fractional probability ofa mouse becom-
ing positive in a given month before the age of5 mo, compared
with after the age 5 mo. Mice were initially bled at age 3 mo
and, if positive at that time, were considered to have become
positive in the previous month (i.e., ages before 2 mo were not
counted). As shown in Table II, the chance of becoming posi-
tive for anti-Sm antibodies was greater for younger than for
older mice, particularly using the more stringent ELISA crite-
ria. For a cutoff value of 0.700, for example, a mouse had a
0.09 chance of becoming positive in a month before age 5 mo
vs. a 0.03 chance after age 5 mo (P = 0.03). In this entire group
of mice, the overall incidence of anti-Sm positivity by ELISA
ranged from 0.28 to 0.4 depending on the criterion. Therefore,
the 0.25 incidence at age 5 mo is not absolute. After 5 mo,
mice continue to become anti-Sm positive, but their chances
of becoming so are diminished. Furthermore, many of the
mice die soon after 5 mo. The assignment of anti-Sm positiv-
ity at 5 mo, then, although arbitrary, represents a reasonable
qualitative estimation of the population. On the other hand,
the development of anti-Sm positivity occurs over time.
Cage analysis ofanti-Sm positivity. Mice from our colony
are caged after weaning according to their litter and gender.
Therefore, animals from a given cage would share a single set
of parents; they would be siblings of the same sex; and they
would be living in a similar environment. By analyzing the
incidence of anti-Sm positivity in mice from a large set of
different cages, it was possible to determine whether the proba-
bility ofa mouse becoming anti-Sm positive depended on the
cage it lived in. If it did, that would suggest the influence of
genetic, parental, or environmental effects. On the other hand,
if the anti-Sm positive mice were distributed randomly in
various cages, then genetic, parental or environmental factors
could not play a major role. Two groups of mice were ana-
lyzed. The first group of 194 mice was examined retrospec-
tively. These mice were bled at - age 5 mo and their parents
and litter of origin were not known precisely. Therefore, a
second prospective study was undertaken in which this infor-
mation was known for 142 mice, and all mice were bled at
exactly age 5 mo. In the first study, 46 (23.7%) ofthe mice were
anti-Sm positive, and in the second study, 29 of 142 mice
(21.4%) were positive for an overall incidence of 22.3%. Anti-
Sm positivity was determined by immunodiffusion.
Table III shows the observed distribution of anti-Sm posi-
tivity in 94 cages containing 1 to 10 mice per cage. For exam-
ple, of the 24 cages that housed 4 mice, 12 had 0 mice with
anti-Sm antibodies; 7, 1 such mouse; 3, 2 mice; 1, 3 mice; and
1, 4 mice. Table IV shows the expected distribution ofpositive
mice based on the overall probability of 0.223 and the bino-
mial distribution (see Methods). For example, in the same 24
cages housing 4 mice, 8.6 cages would be expected to have no
anti-Sm positive animals; 10.1 cages, 1 positive animal; and so
on. The expected and observed values were compared by chi-
square analysis in those cages with two to six mice. None ofthe
chi-squared values approached statistical significance. Also,
the chi-square values were summed over all the cages contain-
ing from two to six mice to give a total P value of0.580, which
indicates no significant departure of the observed values from
the expected distribution based on random assignment ofposi-
tive mice.
In the prospective study of 142 mice, it was possible to be
certain of the litter of origin and parental anti-Sm status. The
distribution of anti-Sm positivity by litters was no different
than random (P = 0.598 by chi-square analysis). Similarly, the
parental anti-Sm status (determined at age 5 mo for both
parents) had no significant influence on the eventual develop-
ment of anti-Sm antibodies in offspring, although the small
Table II. Incidence Density ofthe Development ofAnti-Sm Antibody Positivity as Related to Age
Age group
r5 mo >5 mo
ELISA
critenon* No. positive Mouse monthst Incidence densityf No. positive Mouse months Incidence density P"1
0.400 17 159 0.11 7 84 0.08 0.29
0.500 16 160 0.10 5 90 0.06 0.12
0.700 14 163 0.09 3 105 0.03 0.03
* A mouse was counted as positive if it gave an anti-Sm ELISA value for any isotype greater than or equal to the criterion value. The ELISA
positive mice in the .5 mo group were all immunodiffusion positive at 5 mo. $ A mouse month is one mouse at risk to become anti-Sm posi-
tive for 1 mo. A mouse is no longer at risk if it dies or becomes positive. I Incidence density is No. of mice becoming positive per mouse
months. 11 Incidence density compared before and after age 5 mo. (12).
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Table III. Observed Distribution ofMice with Trait by Cage Size*
Observed values (No. of mice per cage)
No. mice with
trait per cage 1 2 3 4 5 6 7 8 9 10 Total
0 5 13 5 12 8 1 1 0 0 0 45
1 4 6 6 7 6 3 0 0 0 0 32
2 2 2 3 2 2 0 0 0 1 12
3 0 1 1 0 0 0 0 0 2
4 1 1 0 0 0 0 0 2
5 0 0 1 0 0 0 1
6 0 0 0 0 0 0
7 0 0 0 0 0
8 0 0 0 0
9 0 0 0
10 0 0
Total cages 9 21 13 24 18 6 2 0 0 1 94
* 94 cages containing 336 mice were typed for anti-Sm at age 5 mo. The table shows cages of different Nos. of mice per cage, and indicates the
numbers of such cages with a given No. of mice with the anti-Sm positive trait.
number of anti-Sm positive parents could have masked a
minor effect (2 anti-Sm positive mice among 15 offspring with
1 positive parent vs. 27 positive mice among 127 offspring of
negative parents, P = 0.76 by the Fisher exact test). Finally, the
males and females of these mice showed no difference in anti-
Sm positivity (16 of 70 males vs. 13 of 72 females, P = 0.536
by the Fisher exact test).
Overall, then, none of the traits identified in this study
could be shown to influence anti-Sm positivity. Additional
mice that were anti-Sm positive were killed, and the Sm con-
tent of their spleens, lymph nodes, and livers were compared
with those of age-matched anti-Sm negative mice. No differ-
ences were seen (Table V). Finally, among those animals living
at least 5 mo the survival of anti-Sm positive mice was no
different from that of anti-Sm negative animals (mean sur-
vival±SD: 18 anti-Sm positive mice, 7.9±2.0 mo; 31 anti-Sm
negative mice, 8.4±2.8 mo).
Discussion
In the current report, we have attempted to explain the epide-
miology of the anti-Sm response in SLE mice. It is clear that
the potential to generate anti-Sm antibodies in the context of
autoimmunity is under genetic control. The MRL/lpr and
MRL/+ mice, because of genes in the MRL background,
spontaneously make anti-Sm autoantibodies. B6 mice, even
under the influence of the lpr gene, which induces several
autoantibodies, including antichromatin and anti-DNA, fail to
make anti-Sm antibodies. It is possible that the genetic ele-
ments that permit the anti-Sm response in the MRL strains
Table IV. Expected Distribution ofMice with Trait by Cage Size
Expected values (No. of mice per cage)*
No. mice with
trait per cage 1 2 3 4 5 6 7 8 9 10
0 7.0 12.6 6.1 8.6 5.0 1.3 0.3 0 0 0.1
1 2.0 7.4 5.2 10.1 7.4 2.3 0.7 0 0 0.3
2 1.0 1.6 4.3 4.1 1.6 0.7 0 0 0.3
3 0.1 1.0 1.3 0.6 0.3 0 0 0.2
4 0 0.2 0.1 0.1 0 0 0.1
5 0 0 0 0 0 0
6 0 0 0 0 0




Total cages 9 21 13 24 18 6 2 0 0 1
* The expected distribution of numbers of positive mice in cages of varying sizes can be computed by the binomial distribution formula, E(x)
= ( )PX( 1 - p)f-x, where n is the number of cages of each cage size (last row of Table III); x, the number of mice with the trait; and P, the over-
all probability of developing the trait in the population (0.223).
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Table V. Sm Antigen in 5-Mo-Old MRL/Mp-lpr/lpr Mice
Tissue lysate*
n Lymph node Spleen Liver
Anti-Sm (® 10 221 (195)* 54 (58) 122 (95)
Anti-Sm () 10 208 (160) 54 (25) 185 (70)
* Tissues were obtained from 5-mo-old animals established to be
anti-Sm positive or anti-Sm negative. They were processed as pre-
viously described (10), and Sm antigen levels were determined by an
ELISA assay.
* Nanograms Sm per microgram DNA (SD).
also favor the markedly more severe autoimmune syndrome
in MRL/lpr mice as compared with B6-lpr mice. This predic-
tion would be consistent with the high specificity of the anti-
Sm response for the diagnosis ofSLE in several species. We are
currently investigating this genetic aspect by a classical breed-
ing analysis.
The other aspect of the epidemiology of the Sm response
that we have explored in this paper is the tendency for an
individual animal with a permissive genotype (i.e., an MRL
mouse) to become anti-Sm positive. This consideration is
prompted by the repeated finding that - 25% of MRL/lpr
mice become anti-Sm positive by age 5 mo. The ELISA data
presented in the current report clearly indicate that the MRL/
lpr mice fall into two populations regarding anti-Sm antibod-
ies: (i) responders, which make high titers ofanti-Sm antibod-
ies as detected by ELISA; and (ii) nonresponders, which show
no more anti-Sm antibodies in their sera than do normal
mice. Therefore, the 25% positivity rate in the MRL mice is a
reflection of fundamental processes in the development ofdis-
ease in individual animals and is not an artifact of an insensi-
tive assay.
The recurrent finding of 25% positivity in the MRL/lpr
mice is even more striking in that the same level of positivity
occurs in both human and canine lupus and in our current
survey of the MRL/+ mice. On the other hand, the concor-
dance ofthese proportions, although highly provocative, needs
to be examined critically. The MRL mice are highly inbred. As
discussed below, the differentiation between anti-Sm positive
and anti-Sm negative individuals of this strain is not on a
genetic basis. In comparison, the human and canine popula-
tions that have been tested are genetically heterogeneous, and
it would not be surprising that one of the factors that play a
role in determining anti-Sm positivity among such individuals
with SLE is genetic. For example, some surveys have shown
that blacks with SLE have a much higher percentage of anti-
Sm positivity than whites (6). Also, there is some arbitrariness
of the 25% figure in the MRL strains. We have chosen to
consider mice at age 5 mo, as that is a time at which disease is
fully developed, but that does not exclude the majority of
animals due to premature death. However, as we point out,
some mice do become anti-Sm positive after age 5 mo, al-
though the tendency to become positive, as measured by inci-
dence density, decreases with age. Therefore, the processes that
determine anti-Sm positivity in individual MRL mice con-
tinue to operate over time.
In this study, then, we have attempted to determine by a
simple cage analysis which factors could influence the develop-
ment of anti-Sm antibodies in individual mice. As the envi-
ronment ofan individual mouse is determined by its cage, and
since we cage our mice by sex and litter, mice from a single
cage would have similar environment, parental influence, and
genetics (if there should be any genetic heterogeneity within
our population). Therefore, if any of these factors should play
an important role in determining anti-Sm positivity, then the
distribution of anti-Sm positive mice over a large number of
cages would not be random, but, rather, positive mice would
be clustered in certain cages and negative mice in others. The
presented results failed to reveal any nonrandom clustering of
anti-Sm reactivity by cage and therefore indicate that none of
these factors plays a major role in determining anti-Sm posi-
tivity. Also, separate consideration of litter, gender, or parental
anti-Sm status also failed to show any significant effect on an
individual mouse's anti-Sm response. Although we of course
cannot rule out minor influences, as we have surveyed a lim-
ited number of mice, the development ofanti-Sm by a consis-
tent proportion of animals cannot be explained by genetic,
parental, or environmental influences.
The results of the cage analysis prompted us to label the
factors that determine anti-Sm positivity in individuals as
"stochastic." This term to some degree reflects our ignorance;
yet, it is difficult to imagine a preprogrammed mechanism in
our genetically and environmentally homogeneous population
that could result in the 25% positivity rate without the essential
effect of a truly random, i.e., unpredictable process. On the
other hand, this does not mean that we cannot investigate this
process further. For example, the finding that the mortality of
anti-Sm positive mice is no different from that of anti-Sm
negative mice suggests that the random process that deter-
mines anti-Sm positivity in individual MRL mice is not one
that has a major influence on the course of disease. This is
consistent with the failure to identify definitive subsets of
human SLE with relation to anti-Sm positivity (13-15). Fur-
thermore, the similarity of tissue Sm antigenic levels in anti-
Sm positive MRL/lpr mice as compared with age-matched
anti-Sm negative animals suggests that the random processes
are not operating through the quantitative expression of anti-
gen (qualitative differences cannot be ruled out). All things
considered, a potentially fruitful direction to investigate for
processes with major random influences that could determine
anti-Sm positivity appears to be the rearrangement, expres-
sion, and mutation of variable region genes for immunoglobu-
lins or for T cell receptors. This approach is attractive since it
would provide an obvious explanation for the specificity ofthe
random process for anti-Sm reactivity. In a sense, this is re-
viving the "forbidden clone" hypothesis ofMacFarlane Burnet
(16), a theory that is currently in disfavor due to the frequent
finding of autoantibodies in a variety of situations (17). The
Sm antibody response, however, is unusual in that the precur-
sors of the response are not detectable in normal or anti-Sm
negative MRL mice (18), even though some must arise, at least
periodically, as MRL mice can uniformly respond to immuni-
zation with exogenous Sm (19). An additional complication
for a forbidden clone hypothesis is the fact that the fully devel-
oped anti-Sm response, both in humans and in mice, is not
monoclonal (1 1, 20).
The polyclonality of the anti-Sm response can be recon-
ciled with the random development of an unusual specificity
in two ways. First, appropriate T cell receptor variable-region
expression could be postulated to occur in only 25% of ani-
Stochastic Control ofAnti-Sm Autoantibodies 695
mals, and this monoclonal T cell response might be necessary
for development of a polyclonal B cell response. We have
already demonstrated a T cell proliferative response to the Sm
antigen, which is genetically restricted to the MRL mice and to
certain normal strains (21). However, all MRL/+ mice are
potential responders, and there is no difference between anti-
Sm positive and anti-Sm negative individuals (22). Although
the connection between the T cell proliferative response to Sm
that we have investigated and a possible role for anti-Sm-spe-
cific T cells in vivo is not clear, we feel that the current evi-
dence is against T cell receptor specificity being the determin-
ing factor between anti-Sm positive and anti-Sm negative
MRL mice. This is further substantiated by our failure to dem-
onstrate either spontaneous anti-Sm-specific help or suppres-
sion in the MRL mice (23).
The working hypothesis we favor at present is that the
initial anti-Sm response depends upon the effective expression
of anti-Sm recognizing immunoglobulin variable regions.
This event would occur with a 0.25 probability by the age 5
mo. The generation of these variable regions may depend on
any of the mechanisms that are now known to determine im-
munoglobulin antigen binding sites (24). The eventual poly-
clonality of the response would result from somatic diversifi-
cation ofthe initial clone (25). This mechanism would explain
the isoelectric focusing heterogeneity we have observed for
both human and mouse anti-Sm antibodies, but would not be
compatible with our light chain results in human sera (20).
Another mechanism that may play a role is antibody-mediated
positive-feedback enhancement, since the injection ofa mono-
clonal anti-Sm antibody stimulates the production of endoge-
nous anti-Sm antibodies in both MRL/+ and MRL/lpr mice
(26, 27).
The stochastic nature of the anti-Sm response in MRL
mice is probably not unique to this particular autoantibody.
Whereas the phenomenon'is especially striking in this case,
perhaps secondary to the feedback amplification by passive
antibody, it is highly likely that multiple aspects of the au-
toimmune disease in these mice and in other species are go-
verned by random processes. Therefore, it is not surprising
that there is a spectrum of findings regarding any disease pa-
rameter one chooses to investigate, e.g., mortality, glomerulo-
nephritis, rheumatoid factor, and etc. Although historically the
individual variation in genetically inbred mice has merely pre-
sented difficulties regarding the analysis of data, from the
present point of view it represents an opportunity to study
mechanisms that are neither environmental nor genetic, but
that may have a major influence on important disease mani-
festations. Similar considerations should be kept in mind in
the analysis of human data for identical twins (28). Although
the failure to find 100% concordance for the presence of SLE
between identical twins has generally been interpreted to indi-
cate the importance of environmental influences, it is also
possible that stochastic processes are the major determinants
in this situation. In fact, Burnet has already applied such rea-
soning to SLE (16). Assuming a background ofgenetic suscep-
tibility and the influence of stochastic processes over time, he
was able to develop mathematically incidence density curves
that are consistent with the known epidemiology of human
SLE. Our findings for the anti-Sm response in MRL/lpr mice
represent a qualitative validation of this approach.
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